Aggressive Surgical Resection Combined With Low-dose Ril 2-based Adoptive Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma (mrcc); Surgical Biology of a Large Multi-center Randomized Placebo Controlled Phase Ii/iii Study